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the diagnosis and therapeutic monitoring of Trichosporon
fungemia than serum b-D-glucan
With the increasing incidence of invasive trichosporonosis, this
disease is now receiving more attention from physicians. Nakase
et al. considered the elevation of serum (1–3)-b-D-glucan (BDG)
levels a paradoxical sign for Trichosporon fungemia in patients with
hematologic disorders.1 BDG is a fungal cell wall polysaccharide that
is released into the bloodstream of patients in most invasive fungal
infections (IFIs), with the exception of invasive zygomycosis and
cryptococcosis. Until now, all relevant studies have only assessed the
performance of BDG assays for the early diagnosis of IFIs in high-risk
patients.2 To date, the clinical value of BDG-based tests for
monitoring the effect of antifungal therapy and predicting the
outcome of IFIs has not been ﬁrmly established, as data from clinical
studies remain scarce. The potential for false-positive results and
their inability to differentiate between yeast and mould infections
limits the clinical use of BDG-based assays.3 Fungal-speciﬁc antigen
testing would have a higher predictive value for diagnosis and
treatment, such as the glucuronoxylomannan (GXM) antigen for
Cryptococcus infections.4 When compared to Candida spp, Trichos-
poron asahii was found to release comparable BDG levels in vitro, but
showed a lower reactivity (62%) with the BDG test.5 In experimental
disseminated trichosporonosis, the serum level of BDG was reduced
by antifungal therapy and correlated well with the CFU/organ in the
kidney, but did not have a strong relationship with CFU/ml in blood.6
Serum Trichosporon spp antigen cross-reactivity with Crypto-
coccus neoformans capsular polysaccharide has been reported in
patients with Trichosporon fungemia for a long time.7 Lyman et al.
found that all the clinical and non-clinical isolates of Trichosporon
beigelii produced cross-reactive antigen. The amount of the GXM-
like polysaccharide antigen produced by isolates from invasive
infections was signiﬁcantly higher than that produced by
superﬁcial infection-derived or environmental isolates.8 Another
study also found that T. asahii GXM antigen levels released by
clinical isolates were signiﬁcantly higher than those of environ-
mental isolates. Conversely, the environmental isolates released
signiﬁcantly higher amounts of BDG than clinical isolates. Passage
through mice was clearly associated with a progressive increase in
GXM antigen release, but there were no signiﬁcant changes in BDG
release.9 The capsular GXM polysaccharide from C. neoformans is a
well described virulence factor for this organism.4 Fonseca et al.
found that both trichosporal and cryptococcal GXMs share the
same common domains and antigenic determinants. They were
similar in cell wall anchoring and antigenic and anti-phagocytic
properties.10 These ﬁndings suggest that the serum T. asahii GXM
antigen, which is cross-reactive with cryptococcal GXM antigen, is
a better target to test for Trichosporon fungemia than BDG.
However, further clinical and laboratory studies are needed to
determine the possible application of testing T. asahii GXM antigen1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.03.009in the early diagnosis and monitoring of invasive trichosporonosis
for high-risk populations. Eventually, combined testing of serum
GXM and BDG levels may be a more suitable means of diagnosing
and monitoring the progression of Trichosporon fungemia.
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